These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 1544843

  • 1. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
    Workman P, Binger M, Kooistra KL.
    Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
    [Abstract] [Full Text] [Related]

  • 2. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
    Verweij J, Aamdal S, Schellens J, Koier I, Lund B.
    Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
    [Abstract] [Full Text] [Related]

  • 3. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
    McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B.
    Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.
    Cummings J, Spanswick VJ, Gardiner J, Ritchie A, Smyth JF.
    Biochem Pharmacol; 1998 Feb 01; 55(3):253-60. PubMed ID: 9484790
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, Koier I, Krediet RT, Stoter G, Verweij J.
    J Natl Cancer Inst; 1994 Jun 15; 86(12):906-12. PubMed ID: 8196081
    [Abstract] [Full Text] [Related]

  • 6. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar RE, Fiebig HH, Double JA.
    Eur J Cancer; 1993 Jun 15; 29A(6):897-906. PubMed ID: 8484984
    [Abstract] [Full Text] [Related]

  • 7. Bioreductive agents: a clinical update.
    Boyer MJ.
    Oncol Res; 1997 Jun 15; 9(6-7):391-5. PubMed ID: 9406245
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.
    Loadman PM, Bibby MC, Phillips RM.
    Br J Pharmacol; 2002 Nov 15; 137(5):701-9. PubMed ID: 12381684
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
    Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Calabresi F, Paridaens R, Monfardini S, Wolff J, Loos WJ, Verweij J, Pavlidis N, Hanauske AR, EORTC Early Clinical Studies Group.
    Anticancer Drugs; 2001 Aug 15; 12(7):583-90. PubMed ID: 11487714
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM, Phillips RM, Lim LE, Bibby MC.
    Biochem Pharmacol; 2000 Apr 01; 59(7):831-7. PubMed ID: 10718341
    [Abstract] [Full Text] [Related]

  • 11. Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
    Schellens JH, Loos W, Beijnen JH, Stoter G, Verweij J.
    J Chromatogr; 1993 Jun 02; 615(2):309-15. PubMed ID: 8335709
    [Abstract] [Full Text] [Related]

  • 12. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
    Plumb JA, Workman P.
    Int J Cancer; 1994 Jan 02; 56(1):134-9. PubMed ID: 8262670
    [Abstract] [Full Text] [Related]

  • 13. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
    Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):295-9. PubMed ID: 8195022
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
    Aamdal S, Lund B, Koier I, Houten M, Wanders J, Verweij J.
    Cancer Chemother Pharmacol; 2000 May 15; 45(1):85-8. PubMed ID: 10647507
    [Abstract] [Full Text] [Related]

  • 15. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
    Smitskamp-Wilms E, Hendriks HR, Peters GJ.
    Gen Pharmacol; 1996 Apr 15; 27(3):421-9. PubMed ID: 8723519
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
    Kestell P, Pruijn FB, Siim BG, Palmer BD, Wilson WR.
    Cancer Chemother Pharmacol; 2000 Apr 15; 46(5):365-74. PubMed ID: 11127940
    [Abstract] [Full Text] [Related]

  • 17. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
    Adams GE, Stratford IJ, Edwards HS, Bremner JC, Cole S.
    Int J Radiat Oncol Biol Phys; 1992 Apr 15; 22(4):717-20. PubMed ID: 1544844
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M, Workman P.
    Cancer Chemother Pharmacol; 1991 Apr 15; 29(1):37-47. PubMed ID: 1742848
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.